A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2018
At a glance
- Drugs BIIB 054 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Acronyms SPARK
- Sponsors Biogen
- 25 Jan 2018 According to a Neurimmune Therapeutics media release, first patient has been dosed.
- 18 Dec 2017 Planned End Date changed from 30 Sep 2021 to 30 Jun 2022.
- 18 Dec 2017 Planned primary completion date changed from 30 Sep 2021 to 30 Apr 2021.